tradingkey.logo

Immunome Announces Positive Topline Results From Phase 3 Ringside Trial Of Varegacestat In Patients With Desmoid Tumors

ReutersDec 15, 2025 12:19 PM

- Immunome Inc IMNM.O:

  • IMMUNOME ANNOUNCES POSITIVE TOPLINE RESULTS FROM PHASE 3 RINGSIDE TRIAL OF VAREGACESTAT IN PATIENTS WITH DESMOID TUMORS

  • IMMUNOME INC - VAREGACESTAT IMPROVES PROGRESSION-FREE SURVIVAL IN PHASE 3 TRIAL

  • IMMUNOME INC - VAREGACESTAT ACHIEVES 56% OBJECTIVE RESPONSE RATE IN TRIAL

  • IMMUNOME INC - VAREGACESTAT WELL TOLERATED WITH MANAGEABLE SAFETY PROFILE

  • IMMUNOME INC - NDA SUBMISSION FOR VAREGACESTAT PLANNED FOR Q2 2026

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Tradingkey

Related Articles

Tradingkey
KeyAI